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Background
The type 1 ryanodine receptor (RYR1) is expressed in
human skeletal muscle and plays a key role in calcium
homeostasis. Most patients with malignant hyperthermia
(MH) have mutations in the RYR1 gene.
Today, the gold standard for MH diagnosis is an inva-
sive open muscle biopsy followed by the in-vitro-con-
tracture-test (IVCT). Less invasive diagnosis using
molecular genetic methods is of increasing importance,
but knowledge about genetic variants in RYR1 is limited.
The European MH Group (EMHG) RYR1 mutation
database is not up-to-date and lacks information on a
significant number of more recently identified variants
or further knowledge on variants already in the data-
base. Therefore, the need for an update in order to
expand the use of molecular genetic testing is required.
The aim of this study was to collect information about
variants in the RYR1 gene and their functional effect.
Finally this information will be imported into the EMHG
RYR1 mutation database.
Materials and methods
PubMed was used for data collection. For the search, the
three keywords “Malignant Hyperthermia”, “Mutation”
and “Ryanodine Receptor Calcium Release Channel”
were used; the operator was “AND”. Publication dates
from the beginning of 2006 to the end of 2012 were
selected. However, some older and newer studies were
also included if they seemed important for the gain of
information. Additionally, the considered papers had to
be relevant for the human species. The software EndNote
X7 (Thomson Reuters, Carlsbad, CA, USA) was used for
administration of references and data was collected and
processed in Microsoft Excel for Mac 2011 (Microsoft
Corporation, Redmont, WA, USA).
Results
Altogether 62 publications were found according to the
search algorithm. In the newly created database, an over-
all of 316 variants were gathered. 143 variants were not
yet in the EMHG database, 129 of them not functionally
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Figure 1 Location of the newly Identified and functionally characterized RYR1 variants in the RYR1 gene. MH I-III: Hot spots in which most MH
associated mutations are found today. MH I = N-terminal region (p.C35-p.R614), MH II = central region (p.D2129-p.R2458), MH III = C-terminal
region (p.l3916-p.G4942). The variant p.H4833Y (in bold) fulfils all criteria to be used in genetic testing and is therefore a causative mutation.
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characterized or non-pathogenic, 13 functionally charac-
terized and putatively causative and one causative
(p.H4833Y), respectively.
Among another 11 variants which were already in the
EMHG database two (p.R530H, p.R2336H) can be classi-
fied as causative (Figure 1).
Conclusions
This study shows that important additional information
on variants in RYR1 was published since 2006. However,
only three mutations (p.R530H, p.R2336H and p.H4833Y)
can be newly classified as causative mutations according
to the EMHG guidelines. The main reason for this
disappointing conclusion is the fact that the criterion “co-
segregation with the disease in at least two pedigrees”
according to the EMHG guidelines was missing in other-
wise MH causative mutations. Nevertheless, this update of
the database gives easier access to genetic information and
emphasizes the increasing significance of genetic testing.
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